{"id":3736,"date":"2018-12-06T12:42:23","date_gmt":"2018-12-06T07:12:23","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3736"},"modified":"2021-07-24T12:57:08","modified_gmt":"2021-07-24T07:27:08","slug":"the-business-cocktail-47","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-47","title":{"rendered":"Roche signs Icagen; UCB devote $255M; Siemens Healthineers celebrates"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Roche signs Icagen in neuro drug discovery deal worth up to USD 274 Million<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Roche and Icagen<\/strong> have signed a licensing and collaboration deal regarding ion channel modulators for <a href=\"https:\/\/www.delveinsight.com\/report-store\/bipolar-disorder-manic-depression-market\">neurological disorders<\/a>. Icagen receives up to <strong>USD 274 million<\/strong> in development and commercial milestones.\u00a0The duo will work on small molecules using Icagen\u2019s platform for ion channels, targeting a specific ion channel target expressed in neurons. The agreement includes Icagen of handling preclinical work up to lead optimization, after that, both partners will work to identify candidates to move into IND-enabling studies. Also, Roche will be responsible for any development and commercialization of the program. Icagen will also receive royalties if the partnership yields a commercialized drug.<\/p>\n<p style=\"text-align: justify;\"><strong>UCB devote <\/strong><strong>USD 255 million<\/strong> <strong>for creating U.K. R&amp;D hub<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>UCB<\/strong> spends <strong>USD 255 million<\/strong> for creating a new <strong>R&amp;D facility<\/strong> in the U.K. The U.K. government has begun by distributing<strong> life science<\/strong> investments details and keeping its Brexit plan to move forward. The deal flunked last year to improve perceptions about the post-Brexit prospects of the U.K. as a location for life science investment. Now, the agreement was revealed to an even more sceptical global industry. The government presented the investments are not likely to dismiss scepticism, however, unlike last year, the government has an important, previously undisclosed initiative to reveal. UCB stepped up to give a boost to the stressed government.<\/p>\n<p style=\"text-align: justify;\"><strong>Siemens Healthineers celebrates USD 300 Million for IVD manufacturing plant project <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Siemens Healthineers<\/strong>, a medical technology company and is headquartered in <strong>Erlangen, Germany<\/strong> held a ribbon-cutting ceremony for its <strong>USD 300 million<\/strong> extensions in vitro diagnostic test manufacturing and R&amp;D facility in Walpole, <strong>Massachusetts<\/strong>. Presently, the flagship Walpole facility employs more than 900 employees and is Healthineers\u2019 main manufacturing plant for tests running on its Advia Centaur family of immunoassay instruments, and also consumables for the company\u2019s molecular and blood gas testing hardware.<\/p>\n<p style=\"text-align: justify;\">\n","protected":false},"excerpt":{"rendered":"<p>Roche signs Icagen in neuro drug discovery deal worth up to USD 274 Million Roche and Icagen have signed a licensing and collaboration deal regarding ion channel modulators for neurological disorders. Icagen receives up to USD 274 million in development and commercial milestones.\u00a0The duo will work on small molecules using Icagen\u2019s platform for ion channels, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3742,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2283,2286,2285,524,2287,2284],"industry":[17226,17225],"therapeutic_areas":[17245],"class_list":["post-3736","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-icagen","tag-life-science","tag-rd-facility","tag-roche","tag-siemens-healthineers","tag-ucb","industry-medical-devices","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Roche-Icagen deal; UCB&#039;s R&amp;B hub; Siemens&#039;s $300M investment<\/title>\n<meta name=\"description\" content=\"Roche and Icagen have signed a licensing and collaboration deal regarding ion channel modulators for neurological disorders.....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-47\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche-Icagen deal; UCB&#039;s R&amp;B hub; Siemens&#039;s $300M investment\" \/>\n<meta property=\"og:description\" content=\"Roche and Icagen have signed a licensing and collaboration deal regarding ion channel modulators for neurological disorders.....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-47\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-12-06T07:12:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/09023957\/pharma-money.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"3000\" \/>\n\t<meta property=\"og:image:height\" content=\"1575\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche-Icagen deal; UCB's R&B hub; Siemens's $300M investment","description":"Roche and Icagen have signed a licensing and collaboration deal regarding ion channel modulators for neurological disorders.....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-47","og_locale":"en_US","og_type":"article","og_title":"Roche-Icagen deal; UCB's R&B hub; Siemens's $300M investment","og_description":"Roche and Icagen have signed a licensing and collaboration deal regarding ion channel modulators for neurological disorders.....","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-47","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-12-06T07:12:23+00:00","article_modified_time":"2021-07-24T07:27:08+00:00","og_image":[{"width":3000,"height":1575,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/09023957\/pharma-money.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-47","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-47","name":"Roche-Icagen deal; UCB's R&B hub; Siemens's $300M investment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-47#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-47#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/09023957\/pharma-money.jpg","datePublished":"2018-12-06T07:12:23+00:00","dateModified":"2021-07-24T07:27:08+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Roche and Icagen have signed a licensing and collaboration deal regarding ion channel modulators for neurological disorders.....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-47"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-47#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/09023957\/pharma-money.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/09023957\/pharma-money.jpg","width":"3000","height":"1575","caption":"alzheimer's"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/09023957\/pharma-money-300x158.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Icagen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">life science<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">R&amp;D facility<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Siemens Healthineers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">UCB<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Icagen<\/span>","<span class=\"advgb-post-tax-term\">life science<\/span>","<span class=\"advgb-post-tax-term\">R&amp;D facility<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">Siemens Healthineers<\/span>","<span class=\"advgb-post-tax-term\">UCB<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Dec 6, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Dec 6, 2018 12:42 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3736"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3736\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3742"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3736"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3736"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3736"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}